Back to search results

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Abroad (travel likely)RecruitingPHASE2

Conditions

Richter Syndrome · Chronic Lymphocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mount Sinai- Icahn School of Medicine, New York, New York, United States

    Contact: Study coordinator (Suchitra Sundaram, MD)
    Contact: Principal Investigator (Suchitra Sundaram, MD)

  • Columbia University Medical Center, New York, New York, United States

    Contact: Study coordinator (Andrew Lipsky, MD)
    Contact: Principal Investigator (Andrew Lipsky, MD)

  • Weill Cornell Medicine, New York, New York, United States

    Contact: Study coordinator (Amelyn Rodriguez, R.N.) · amr2017@med.cornell.edu · 2127461362
    Contact: Study coordinator (Katherine Greig, R.N.) · kag9156@med.cornell.edu · 2127466738
    Contact: Principal Investigator (John Allan, M.D.)

  • Ohio state University, Columbus, Ohio, United States

    Contact: Study coordinator (Adam Kittai)
    Contact: Principal Investigator (Adam Kittai, MD)
Study leads

  • John Allan, M.D.

    Principal Investigator

    Weill Medical College of Cornell University

View source on ClinicalTrials.gov(opens in a new tab)